Shots: Under the amended agreement, AcelRx to acquire Tetraphase for $30M ($24.6M in stock and $5.4M in cash) with an additional $14.5M in CVRs, payable in cash. The transaction is […]readmore
Tags : Amendments
Mylan to pay $5M up front in addition to $25M (according to 2018 deal), contingent payments ~$100M, ~$225M milestones on the achievement of specified clinical and regulatory milestones and royalties […]readmore